Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP14 | Q460N5 | 3/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.51 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.47 |
| ▸ | SCD | O00767 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3379273 | 0.83 | ALDH1A1 (0.54) | L3MBTL1MBTD1L3MBTL3ALDH1A1 | |
| SCHEMBL3380993 | 0.82 | MBTD1 (0.40) | PARP14PARP10L3MBTL1MBTD1L3MBTL3 | |
| SCHEMBL3377190 | 0.80 | NAMPT (0.47) | L3MBTL1MBTD1L3MBTL3ALDH1A1POLB | |
| SCHEMBL3377139 | 0.78 | SMN1; SMN2 (0.56) | PARP14PARP10L3MBTL1ALDH1A1 | |
| SCHEMBL3377903 | 0.74 | KMT2A (0.42) | CA12CA1CA2CA9MGLL | |
| SCHEMBL10720211 | 0.73 | CA12 (0.76) | PARP14PARP10L3MBTL1L3MBTL3CA12 | |
| SCHEMBL10723485 | 0.73 | ALDH1A1 (0.62) | L3MBTL1L3MBTL3CA12CA1CA2 | |
| SCHEMBL3378130 | 0.73 | KMT2A (0.42) | ALDH1A1HSD11B1 | |
| SCHEMBL3900559 | 0.71 | AVPR1A (0.61) | PARP14PARP10L3MBTL1CA12CA1 | |
| SCHEMBL4206605 | 0.70 | CA12 (0.71) | PARP14PARP10L3MBTL1L3MBTL3CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342177-B1 | NOVEL POTASSIUM CHANNEL BLOCKERS | JAPAN TOBACCO INC (JP) | 2017-02-15 | — | — | EP | claimed |
| US-9447033-B2 | Potassium channel blockers | JAPAN TOBACCO INC. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-20150259282-A1 | Potassium Channel Blockers | XENTION LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-9073834-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2015-07-07 | — | — | US | disclosed |
| US-20140221337-A1 | Potassium Channel Blockers | XENTION LIMITED (GB) | 2014-08-07 | — | — | US | disclosed |
| US-8673901-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2014-03-18 | — | — | US | disclosed |
| US-20100087428-A1 | Novel Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221337-A1 | Potassium Channel Blockers | KCNJ2, KCNH2, KCNB1 | PARP14 1195/4885PARP10 1052/4885L3MBTL1 1040/4885 |
| US-20100087428-A1 | Novel Potassium Channel Blockers | HCN4, SCN2B, KCNH2 | PARP14 3364/4885PARP10 3415/4885L3MBTL1 3199/4885 |
| US-20150259282-A1 | Potassium Channel Blockers | KCNJ2, KCNH2, KCNB1 | PARP14 1195/4885PARP10 1052/4885L3MBTL1 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.